Introduction
Nucleophosmin (NPM) is a nucleocytoplasmatic shuttling protein with prominent nuclear localization, and is implicated in ribosomal protein assembly and transport as well as in prevention of nucleolar protein aggregation. It regulates the ARF-p53 tumor suppressor pathway by modulating the transcriptional activity of p53 after different types of stress.
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The NPM gene is involved in several leukemia and lymphoma-associated chromosome translocations that result in fusion proteins retaining the amino terminus of NPM. These include t(2;5)(p23;q35), which creates the chimeric protein NPM-ALK in anaplastic large cell lymphoma, 5 t(5;17)(q35;q21), which creates the fusion protein NPM-RARa 6 and t(3;5)(q25;q35), which involves the myeloid leukemia factor 1. 7 As NPM is thought to have a tumor suppressor function, perturbations in its movement from the nucleous to the cytoplasm may be critical for malignant transformation.
The presence of different types of mutations in NPM exon 12 has been described in the leukemic blast population of a subgroup of AML patients with normal karyotype, resulting in the shift of NPM into the cytoplasm. 8 Moreover, several clinical studies indicate a higher rate of complete remission after chemotherapy in patients carrying the NPM mutation when compared to wild type (NPM wt ), [9] [10] [11] [12] [13] although the molecular basis of this observation remains at present unclear. Nuclear factor-kB (NF-kB) is a transcription factor involved in many biological processes including proliferation, tumor promotion and apoptosis, thereby contributing to the maintenance and survival of malignant clones and impaired response to therapy. 14, 15 NF-kB has been demonstrated to be abnormally activated in blast cells from a significant number of AML patients, 16 and it is thought to be involved in the pharmacological resistance to many chemotherapeutic agents, leading thus to the exploitation of NF-kB inhibitors as a strategy for increasing the rate of chemotherapy sensitivity. 17 NF-kB has a complex pathway of regulation controlled by the activation of different tyrosine kinases. It is mainly localized in the cytoplasm in the inactive form bound to its inhibitor, the IkB kinase. IkB kinase, through the phosphorylation of IkB, tags IkB for polyubiquitination by a specific ubiquitin-ligase. IkB proteins are rapidly degraded by the proteasome, thereby freeing NF-kB to enter the nucleus where it binds to DNA and activates transcription. 18 Data published by Dhar et al. 19 demonstrated the physical nuclear interaction between NPM and NF-kB proteins. On the basis of this assumption, this study focuses on understanding the mechanism underlying the chemosensitivity induced by NPM delocalization, mainly through the analysis of the cytoplasmatic interactions between NPMc þ and NF-kB.
Materials and methods

Patients
After informed consent, bone marrow (BM) cells were collected from 109 acute myeloid leukemia (AML) patients at diagnosis. All cases were characterized at the cytogenetic level by conventional karyotyping, and screened by reverse transcriptase-PCR for the presence of the most frequent fusion transcripts as described previously. 20 21 was incubated with daunorubicin and ARA-C at the same culture conditions (Figure 3b) .
At the end of incubation, apoptosis was evaluated by fluorescence-activated cell sorting for the detection of annexin V.
Apoptosis
Apoptosis was evaluated by flow cytometry for the detection of annexin V-positive cells. BM cells incubated with etoposide, daunorubicin and ARA-C and control cells were labeled with annexin V conjugated with fluorescein isothiocyanate and propidium iodide. Briefly, cells were washed once in phosphate buffered saline and once in 1x-binding buffer, then 5 ml of annexin V-fluorescein-S-isotyocianate (FITC) was added to the cells. Cells were incubated at room temperature for 15 min, after which 300 ml 1x-binding buffer was added and cells were analyzed by flow cytometry. Apoptotic cells were defined as annexin V positive and propidium iodide negative.
Measurement of NF-kB activity
Nuclear factor-kB basal activity was determined by the ELISA method (TransAM ELISA kit, Active Motif, Inc., Carlsbad, CA, USA) as reported previously. 21 All the experiments were performed in triplicate and the final numerical value is expressed as mean adsorbance value±s.d. The activity was further confirmed by electrophoretic mobility shift assay.
Electrophoretic mobility shift assay
The NF-kB consensus and mutant oligonucleotide sequences were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). The probes were labeled with T4 polynucleotide kinase (Life Technologies, Gaithersburg, MD, USA) and [32P]-ATP (NEN, Boston, MA, USA) and purified over a Sephadex G25 (Amersham Pharmacia Biotech Inc., Uppsala, Sweden) column. 40 mg of protein nuclear extracts were incubated with 2 mg poly d(I-C) (Roche Molecular Biochemicals, Indianapolis, IN, USA) and 10214 mol 32P-labeled probe in 10 mM 2-hydroxyethyl-1-piperazineethane sulfonic acid (HEPES), 5 mM Tris, 50 mM KCl, 1.2 mM EDTA and 10% (vol/vol) glycerol (pH 7.8) for 30 min at room temperature. A 200-fold molar excess of unlabeled oligonucleotide (nuclear factor-kB consensus or mutant) was added for competition assays. Protein/DNA complexes were resolved on 6% native polyacrylamide gels in 0.25 3 tris-borate-EDTA (TBE) (25 mM Tris, 22.5 mM boric acid and 0.25 mM ethylenediaminetetraacetic acid (EDTA)). Gels were visualized by autoradiography using MS-BioMax film and intensifying screens (Kodak, Rochester, NY, USA).
Western blot
Western Blot was performed as described previously, 22 using both nuclear and cytoplasmatic extracts. NPM policlonal antibody (Affinity Bioreagents, Golden, CO, USA) and p65 policlonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), both at 1:1000 dilution, were used. Moreover, b-actin monoclonal antibody (Sigma Aldrich, St Louis, MO, USA) was used at 1:1000 dilution. The autoradiograms obtained were scanned and exported for densitometry analysis. Proteins signal intensities were measured using NIH 1.63 software. Unless noted differently, each experiment was repeated three times independently. The signal quantity was normalized against the background of each individual autoradiogram and renormalized against the signal obtained with the unrelated protein a-tubulin (CP06; Oncogene Research Products) or lamin (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Immunoprecipitation
Nuclear and cytoplasmatic extracts were used for immunoprecipitation assays. Briefly, 1 mg of extract was incubated for 3 h at 4 1C with 4 mg of p65 policlonal antibody and subsequently for 45 min at 4 1C with Protein A Sepharose (Amersham Bioscience, GE Healthcare, Waukesha, WI, USA). Samples were then blotted with NPM antibody.
Immunofluorescence assay
Immunofluorescence assays using both p65 and NPM antibodies were performed as described previously. 21 The antibody-antigen complexes were detected by incubation for 30 min with secondary goat anti-rabbit Alexa Fluor 568 immunoglobulin G antibodies (1:1000, molecular probes). Cells were then treated with 4,6 diamino-2-phenylindole (DAPI) for 5 min to stain the nucleus and analyzed with confocal scanning microscope (LSM 5110; Carl Zeiss MicroImaging Inc., Thornwood, NY, USA) and images were captured using 100 Â objectives. Fluorescent signal was measured by image processing and analysis in Java (Image J) program.
Results
Different sensitivity to chemotherapeutical agents characterizes NPMc þ and NPM wt cells
To test sensitivity to chemotherapeutical agents, NPMc þ and NPM wt, mononuclear cells were incubated with 10 mM etoposide for 72 h. As shown in Figure 1a , after etoposide incubation, the percentage of apoptotic cells is higher in NPMc þ as compared to NPM wt . The mean value of annexin V-positive cells in untreated NPM wt is 7.8 ± 0.8 cells and 11.2 ± 1.9 after etoposide incubation. By contrast, in NPMc þ untreated cells, the mean value is 8.8 ± 1.4, which increased to 38 ± 3.3 after etoposide incubation. Furthermore, daunorubicin incubation induces a significantly higher rate of apoptosis in NPMc þ cells as compared to NPM wt cells (44±4 vs 17±2) (Figure 1b 
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which is approximately 55% as compared to the activity in NPM wt cells. The NF-kB activity has been measured in five NPMc þ and five NPM wt samples and in OCI-AML3 cells after incubation with chemotherapeutical agents. We found that NF-kB activity is not significantly increased in OCI-AML3 cells after treatment with etoposide, daunorubicin and ARA-C showing a basal value of 0.2, which increased to 0.4, 0.35 and 0.42, respectively. In five BM samples with the NPMc þ , the mean basal level is 0.3 ± 0.1 before incubation and 0.4 ± 0.1 0.35 ± 0.2 and 0.45±0.2 after incubations, respectively. By contrast, in five samples with wild-type NPM, the mean basal level is 5.2 ± 3 and it increases to a value of 15±6, 14±3 and 18±3, respectively, after incubations (Figure 3b ).
Immunofluorescence assay
Immunofluorescence analysis for the detection of NPM localization confirmed the presence of NPM at the nuclear level in NPM wt patients and the delocalization of the protein in NPMc þ patients (data not shown). By using p65 antibody, we detected an equal distribution of p65 in the cytoplasm and in the nucleous ( Figure 5A , a) in NPM1 wt patients and a significant increase in the amount of cytoplasmatic p65 in NPMc þ cells ( Figure 5B, b) .
The quantification of the p65 fluorescent signal in the NPM wt cells shows a mean value of intensity of 25.4±2 in the nucleous and 22.4 ± 1.7 in the cytoplasm. By contrast, in NPMc þ cells, NF-jB activity in NPM1 mutated AML patients D Cilloni et al the mean value of p65 intensity is 6.6 ± 0.8 in the nucleous and 16.7±1.1 in the cytoplasm. In normal subjects, the mean value of p65 intensity is 1.6 ± 0.5 in the nucleous and 2.8 ± 0.7 in the cytoplasm. Furthermore, immunofluorescence using p65 antibody allows to demonstrate that in NPMc þ NF-kB localization remains mainly cytoplasmatic also after incubation with etoposide, daunorubicin and ARA-C (Figure 5B, a) . By contrast, in NPM wt cells, the nuclear signal increases after incubation with the three chemotherapeutical agents mentioned above ( Figure 5B, b) .
Western blot and immunoprecipitation
In line with the results obtained by immunofluorescence, western blot detected NF-kB protein in both nuclear and cytoplasmatic fractions (Figure 6a ). In NPM wt cells, p65 is mainly localized at the nuclear level. The quantification of the bands (b) allows us to calculate that the nuclear fraction is more than twofold that of the cytoplasmatic one. Interestingly, in NPMc þ cells, the cytoplasmatic fraction is 17 times higher than the nuclear one. If we compare the two nuclear fractions, which represent the amount of protein, which can potentially own transcriptional activity, it is 13 times lower in NPMc þ cells than in NPM wt and the cytoplasmatic fraction is more than three time higher.
To evaluate the binding of the delocalized NPMc þ protein with the inactive cytoplasmatic form of NF-kB, coimmunoprecipitation experiments were carried out demonstrating that the two proteins physically interact within the cytoplasm in NPMc þ patients (Figure 7 ). By contrast, in NPM wt cells, the interaction takes place mainly at the nuclear level.
Discussion
The discovery of NPM mutations represents a significant improvement in the molecular characterization of leukemia patients and may provide a relevant prognostic indication. The role of NPM mutations in influencing the overall survival is widely recognized 10, 23 The better responsiveness to chemotherapy of NPMc þ patients seems to be, at present, a common finding observed in evidence by all clinical trials. [9] [10] [11] [12] [13] Based on the current knowledge, the chemosensitivity does not seem to be influenced by the presence of other genetic abnormalities. The presented data illustrate at least one of the mechanisms leading to chemotherapy-induced apoptosis in NPMc þ cells. Our in vitro data are in accordance with these latter observations showing a better chemosensitivity of NPMc þ patients regardless of the presence of FLT3 mutations, which, by contrast, influences the relapse rate in vivo and finally the overall survival. 
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etoposide ARA-C daunorubicin Figure 5 (A) Immunofluorescence using p65 antibody in NPM wt (a) and NPMc þ (b) patients. Nucleous is staining in red, the specific fluorescence is green. In NPM wt cells, the signal is mainly nuclear (yellow signal derived by red and green merging) and NPMc þ is mainly cytoplasmatic. (B) Immunofluorescence using p65 antibody in NPMc þ (a) and NPM wt patients (b) after incubation with 10 mM daunorubicin, 10 mM etoposide and 100 nM ARA-C. NPM, nucleophosmin, NPMc þ , cytoplasmatic NPM; NPM wt, wild-type NPM.
NF-jB activity in NPM1 mutated AML patients D Cilloni et al NF-kB is a transcriptional factor and regulates transcription of over 150 genes encoding cell adhesion molecules, cytokines, growth factors, components of the immune systems and antiapoptotic genes such as FLIP, cIAPs, Bcl-2 and Bcl-XL. 24 It is also implicated in the regulation of cell proliferation by controlling D-type cyclins. 25 As NF-kB regulates the expression of a variety of proteins that inhibit apoptosis and promote cell survival and proliferation, it is strongly implicated in carcinogenesis. 26 Furthermore, it is well known that inhibition of NF-kB increases sensitivity to many chemotherapeutical agents. 27, 28 These findings have led to the creation of a large number of compounds targeted toward the NF-kB activation pathway, such as the IKB or IkB kinase inhibitors 29 and the proteasome inhibitors, 30 and to the planning of new clinical trials based on the contemporary administration of these compounds and of the chemotherapeutical agents.
The presented data demonstrate that NF-kB and NPM proteins physically interact within the cytoplasm at locations other than in the nucleous, as already described. In normal cells, the prevalent nucleolar localization of NPM prevents this phenomenon from taking place, but it becomes biologically significant when mutations delocalize the protein in the cytoplasm. This interaction could explain the difference in NF-kB activity in AML patients. Particularly, the reduced nuclear level of NF-kB in NPMc þ cells may probably be due to the sequestration into the cytoplasm by the delocalized NPM mutant protein of the potentially active form of NF-kB. As already described by Gutzman et al. 16 the increased activity of NF-kB is not typical of all patients with AML but is present in about 40% of the cases. These findings are completely in line with our observations. Additionally, we better characterized the subset of patients with the increased activity and we identified the absence of NPM mutations as one of the main characteristics of the patients with abnormal NF-kB activity.
These data, taken together, suggest an intriguing mechanism leading to a physical block of NF-kB induced by the delocalization of a protein which, interestingly, mimics the action of many compounds designed to block this abnormally activated pathway to increase the rate of responsiveness to chemotherapy. NF-jB activity in NPM1 mutated AML patients D Cilloni et al
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